Gavin Redhead, a patient advocate, tells us how heart failure healthtech recommended by NICE helped transform his life.

Independent committees develop our recommendations. NICE committees are made up of people like you. They include experts in health and social care, people who use health and care services and carers.

Thousands of people in England with a type of chronic heart failure are eligible for a new treatment option following our final draft guidance that recommends finerenone for adults with chronic heart ...

Adults with a first episode of psychosis start treatment in early intervention in psychosis services within 2 weeks of referral. Early intervention in psychosis services can improve clinical outcomes, ...

Browse the complete list of all our published health and social care guidance, including guidelines, NICE advice and quality standards ...

There are different ways to get involved in NICE’s work and help us to improve NHS and care services for other people – either those who are like you, or those communities you represent as part of a ...

There is a simple discount patient access scheme for talquetamab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

Some reflux – regurgitating or vomiting of feeds – is normal in babies. It usually gets better on its own, and does not often need any tests or treatment. If you see a healthcare professional about ...

Evidence-based recommendations on elranatamab (Elrexfio) for treating relapsed and refractory multiple myeloma after 3 or more treatments in adults. Next review: More evidence on elranatamab is being ...

intermittently scanned continuous glucose monitoring. HCL systems are only recommended if they are procured at a cost-effective price agreed by the companies and NHS England, and implemented following ...

This guideline covers diagnosing and managing multiple sclerosis in people aged 18 and over. It aims to improve the quality of life for people with multiple sclerosis by promoting prompt and effective ...

Evidence-based recommendations on sotorasib (Lumykras) for previously treated KRAS G12C mutation-positive locally advanced or metastatic non-small-cell lung cancer in adults. Next review: More ...